Updated:
Endologix
Endologix pioneers EVAR and thrombectomy systems, including the DETOUR System and Pounce Thrombectomy System, with VR-based physician training.
Endologix
Endologix operates as a developer of minimally invasive therapies for vascular disease. The firm is known for the DETOUR System, a novel approach to endovascular aneurysm repair, and the Pounce Thrombectomy System, which clears peripheral artery blockages. The company emphasizes a data-driven method, calling clinical evidence its "north star" and launching VR procedural training as a differentiator (per the firm's website, 2025). Endologix focuses on endovascular repair and thrombectomy, covering aortic, peripheral, and venous applications. The product portfolio includes EVAR solutions and the newer Pounce system, targeting interventions for patients underserved by existing devices. Geography spans North America and Europe, with offices in Santa Rosa, California, and support in Italy, Poland, Germany, the UK, and Belgium. The firm does not publicly disclose team size, total deployment, or ownership structure. It operates a single headquarters in Santa Rosa, California, and lists regional contact points in Europe. No recent major operational events have been publicly reported since the Pounce system integration and DETOUR clearance. Endologix structures itself around specific clinical gaps rather than broad device categories. Its use of virtual reality for physician training and a selective product pipeline distinguish it from larger vascular device companies. The firm positions itself as a focused innovator rather than a full-line supplier.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Santa Rosa
Corporate office
Santa Rosa, CA, United States
Sector focus
Frequently asked questions
What vascular conditions does Endologix target?
Endologix focuses on abdominal aortic aneurysms (AAA) and peripheral artery blockages, using the DETOUR System for EVAR and the Pounce Thrombectomy System for clot removal (per the firm's website, 2025).
How does Endologix differentiate itself from larger medical device companies?
Endologix pursues a focused pipeline targeting unmet clinical needs rather than offering a broad product range. It is the first to integrate immersive VR training for physicians, a feature it markets as a training innovation (per the firm's website, 2025).
What is the DETOUR System?
The DETOUR System is Endologix's novel approach to endovascular aneurysm repair, which earned a Medical Device Engineering Breakthrough award. It is designed to address limitations of standard EVAR procedures (per the firm's website, 2025).
Does Endologix disclose its financials or ownership?
No. Endologix does not publicly disclose AUM, revenue, or ownership structure. The firm appears as a private entity, and no funding rounds or investor information are available.
Where are Endologix's operations based?
The main office is in Santa Rosa, California. The firm also lists support offices in Italy, Poland, Germany, the UK, and Belgium (per the firm's website, 2025).
How does Endologix use virtual reality?
Endologix developed a VR-based procedural training program for its EVAR systems, allowing physicians to practice in a simulated environment. It describes this as a first in the EVAR space (per the firm's website, 2025).
What is the Pounce Thrombectomy System?
The Pounce device is a thrombectomy system for removing peripheral arterial clots, now part of Endologix's portfolio. It expands Endologix's focus beyond aneurysm repair into acute limb ischemia (per the firm's website, 2025).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: